Lets hope David and Andrew delivers better than Donald
PERTH, AUSTRALIA - 13 February 2014: SUDA LTD (ASX: SUD), a leader in oromucosal drug delivery, today announces that it has retained Mr. Donald Harrigan M.S.,RPh, Managing Partner at KAD Consultants, located in Dana Point, California USA. Mr.Harrigan and the team at KAD Consultants will provide advice on SUDA’s US regulatorystrategy and will serve as the Company’s US agent for communications with the FDA. Mr. Harrigan is a seasoned regulatory pharmaceutical consultant with more than 30 yearsexperience. He has gained his regulatory expertise through work in industry and as aconsultant both within the USA and internationally. He has successfully guided numerousclients on their US regulatory strategy and dealings with the FDA. Mr. Harrigan has alsofacilitated the timely approval of multiple products, including those regulated by section505(b)(2) of the Food and Drug Act, which is the regulatory path that SUDA is pursuingfor its novel oral spray reformulations in the USA.
SUD Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held